TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2952478
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole gel (0.75%)
Study: 12911186
Drug: Selective Estrogen
Normalized name: Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Estrogen Receptor Modulators (SERMs)
Study: 11091218
Drug: G-CSF (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (1 microg/kg and 5 microg/kg)
Study: 11091218
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg b.i.d)
Study: 9248767
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg racemic nicardipine (conventional preparation)
Study: 9248767
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg racemic nicardipine (conventional preparation)
Study: 9248767
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg sustained-release nicardipine
Study: 8287938
Drug: Nebulized amiloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized amiloride, administered four times daily for two six month periods
Study: 8287938
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered four times daily for two six month periods
Study: 3826597
Drug: Indomethacin (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (rectal administration)
Study: 29872288
Drug: GB 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB 6.25 μg BID
Study: 28387543
Drug: 4-AP 10
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-AP 10 mg extended release
Study: 21466389
Drug: Amlodipine/valsartan (Aml/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (Aml/Val) 5/80 mg
Study: 18543485
Drug: Huanglan Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huanglan Granule (HLG) - one dosage per day, containing milkvetch root, isatis root and basket fern, each 30 g
Study: 18543485
Drug: Ribavirin -
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin - 0.2 g, three times per day
Study: 12482764
Drug: Single caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single caffeine dose (6 mg/kg) 60 min before exercise and placebo 45 min into exercise (CP)
Study: 12482764
Drug: Divided caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divided caffeine dose (3 mg/kg) 60 min before and 45 min into exercise (CC)
Study: 12482764
Drug: Divided caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divided caffeine dose (3 mg/kg) (CC)
Study: 12482764
Drug: Single caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single caffeine dose (6 mg/kg) (CP)
Study: 12482764
Drug: Caffeine doses
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine doses (CP and CC)
Study: 18284032
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 400 mg per day
Study: 18284032
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 mg per day
Study: 18284032
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium gluconate 400 mg per day)
Study: 11865843
Drug: Rapid dipstick
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid dipstick assay for the detection of Salmonella typhi‐specific IgM antibodies
Study: 7793871
Drug: Cefodizime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (50 mg/kg once daily for 10 +/- 3 days)
Study: 7793871
Drug: Ceftriaxone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (50 mg/kg once daily for 10 +/- 3 days)
Study: 7196564
Drug: Photocoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photocoagulation treatment
Study: 29468508
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block (BSCPB) with 0.25% bupivacaine plus tizanidine 6 mg capsule (Group SC+T)
Study: 29468508
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block (BSCPB) with 0.9% saline plus oral placebo (Group C)
Study: 21901320
Drug: Donepezil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (0.5 mg/kg)
Study: 21901320
Drug: Donepezil (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (1.0 mg/kg)
Study: 21901320
Drug: Scopolamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.3 mg)
Study: 11120963
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate 120 mg by injection (group 1 and group 2)
Study: 11120963
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate 240 mg by infusion (group 3)
Study: 8137478
Drug: 4'-epidoxorubicin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4'-epidoxorubicin (70 mg) alone (group A)
Study: 8137478
Drug: Lipiodol emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol emulsion with 4'-epidoxorubicin (70 mg) (group B)
Study: 26031368
Drug: Neoadjuvant capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant capecitabine combined with oxaliplatin (CAPOX) followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab.
Study: 24378824
Drug: Urinary calprotectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary calprotectin concentrations in bladder cancer patients (522.3 ng/ml)
Study: 24378824
Drug: Calprotectin concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calprotectin concentrations in low grade tumors (351.9 ng/ml)
Study: 21899798
Drug: Lactobacillus paracasei
Normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus paracasei ssp. paracasei (L. casei 431®)
Study: 17126335
Drug: Oxiplex/AP gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiplex/AP gel treatment (treated group)
Study: 10592423
Drug: Parenteral fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral fluids with diazepam
Study: 10592423
Drug: Parenteral fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral fluids without diazepam (control group)
Study: 1765205
Drug: PGE2 pessaries
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 pessaries (2.5 mg) 1‐2 a day
Study: 1765205
Drug: PGE2 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 (0.5 mg) in a viscous intracervical gel once daily
Study: 31780429
Drug: Back massage
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back massage (twice per day in the morning and evening)
Study: 28176487
Drug: Lornoxicam Immediate-Release
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam Immediate-Release Tablets (8 mg/tablet)
Study: 17687149
Drug: Weekly bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bolus CPT‐11 plus FU plus LV
Study: 17687149
Drug: Weekly bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bolus FU plus LV (control)
Study: 14694457
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg bid (Ta)
Study: 14694457
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg bid plus PFME (Tp)
Study: 11405384
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg nabumetone
Study: 9990362
Drug: Cyclosporin at
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin at an initial dose of 1 mg/kg per day
Study: 17613971
Drug: Residential Treatment
Normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential Treatment (RT)
Study: 23670354
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg daily for 12 weeks
Study: 19473604
Drug: Brethmol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brethmol (4 mg)
Study: 19473604
Drug: Ventolin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin (4 mg)
Study: 14982045
Drug: Dorzolamide 2%/Timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2%/Timolol 0.5% combination (COSOPT) eye drops twice daily
Study: 14982045
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% (XALATAN) eye drops once daily
Study: 31911179
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera (MO) 400 mg/kg body weight
Study: 31911179
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera hard gelatin capsules
Study: 28805348
Drug: Levocarnitine administered
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine administered 0 and 30 min before each hemodialysis session
Study: 28805348
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 0 and 30 min before each hemodialysis session
Study: 23601628
Drug: Exercise prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise prescription based on physical fitness test results and personal choice
Study: 21480939
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) combined with oral hygiene instructions (OHI)
Study: 21480939
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions (OHI) alone
Study: 19797730
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (DXM) 40 mg/day for four consecutive days
Study: 14760910
Drug: Control (Dentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Dentin chips obtained before treatment)
Study: 1732569
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of 11 mg/kg of amikacin every 12 hours
Study: 31425751
Drug: 1-step: 2-h,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-step: 2-h, 75 g, oral glucose tolerance test (OGTT)
Study: 31425751
Drug: 2-step: 1-h,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-step: 1-h, 50 g glucose challenge test (GCT) followed by 3-h, 100 g OGTT if GCT-positive
Study: 28737128
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of oseltamivir 75-mg capsule
Study: 28737128
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation Tamiflu®
Study: 27566367
Drug: Adalimumab with
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab with azathioprine (25-100mg daily)
Study: 25332331
Drug: Hypocaloric nutritional
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric nutritional support (50% of calculated daily caloric requirement of 25-30 kcal · kg(‐1) · d(‐1))
Study: 25332331
Drug: Eucaloric nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucaloric nutritional support (standard calculated daily caloric requirement of 25-30 kcal · kg(‐1) · d(‐1))
Study: 19930005
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine o.d.
Study: 17966778
Drug: New graduated
Approvals — FDA: no, EMA: no, PMDA: no
Description: New graduated dilator with a standard treatment schedule (20 patients)
Study: 17966778
Drug: Multiple anal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple anal dilators (20, 23, 27 mm) with a standard treatment schedule (20 patients)
Study: 17966778
Drug: New graduated
Approvals — FDA: no, EMA: no, PMDA: no
Description: New graduated dilator according to a free treatment schedule (20 patients)
Study: 17966778
Drug: Graduated anal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graduated anal dilator according to a free treatment schedule
Study: 30734085
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg calcium supplement
Study: 25943912
Drug: Conventional Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Care (CC-1)
Study: 25943912
Drug: Conventional Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Care (CC-2)
Study: 18323492
Drug: Constraint‐induced movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced movement therapy
Study: 22221683
Drug: Lidocaine group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine group (n = 40): 1 mL (10 mg) nalbuphine diluted with 1 mL lidocaine (20 mg)
Study: 22221683
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (control) (n = 40): 1 mL (10 mg) nalbuphine diluted with 9 mL normal saline
Study: 12752837
Drug: Multifactorial fall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial fall prevention program (staff education, environmental adjustment, exercise, drug review, aids, hip protectors, postfall problem-solving conferences)
Study: 9193126
Drug: Self-directed treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed treatment with minimal therapist contact (five meetings, readings, self-directed exposure with response prevention)
Study: 9193126
Drug: Waiting period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting period (6-week delay before treatment)
Study: 1735279
Drug: bid dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid dosing (4 inhalations bid)
Study: 1735279
Drug: qid dosing
Normalized name: MINOXIDIL 5 g in 100 mL / BIOTIN 5 g in 100 mL EXTRACORPOREAL AEROSOL, FOAM [QIDILA 5% Minoxidil Foam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: qid dosing (2 inhalations qid)
Study: 26381054
Drug: Macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan 10 mg at steady state
Study: 26381054
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptive (OC) alone (reference)
Study: 23354115
Drug: Teriparatide (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (daily subcutaneous injection of 20 μg)
Study: 23354115
Drug: Bisphosphonate (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate (daily oral administration of 2.5 mg of risedronate)
Study: 23354115
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without medication for osteoporosis)
Study: 7042888
Drug: Fresh concentrated
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh concentrated Egyptian liquid BCG vaccine (2 mg/ml) given in gradually increasing doses.
Study: 7042888
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (11 patients) did not receive any further treatment after chemotherapy.
Study: 30446398
Drug: Drug-Eluting Stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stents (DES) with longer DAPT (>6 months)
Study: 30446398
Drug: Drug-Eluting Stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stents (DES) with shorter DAPT
Study: 28771493
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (LNS) 20g daily
Study: 23829890
Drug: nab-P 260
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P 260 mg/m(2) q3w with bevacizumab 15 mg/kg q3w
Study: 23829890
Drug: nab-P 260
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P 260 mg/m(2) q2w with filgrastim and bevacizumab 10 mg/kg q2w
Study: 23829890
Drug: nab-P 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P 130 mg/m(2) weekly with bevacizumab 10 mg/kg q2w
Study: 20890204
Drug: Tinnitus retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus retraining therapy (TRT) with acoustic stimulation devices and 3 months of individual counseling
Study: 20890204
Drug: General counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: General counseling without additional sound therapy
Study: 9699090
Drug: Increased urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urinary albumin excretion (UAE)
Study: 8120515
Drug: Selenium and
Normalized name: Selenium and/or selenium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium and vitamin E treatment (1.6 mg selenium and 800 mg vitamin E daily for 4 months)
Study: 8120515
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (corresponding number of placebo tablets)
Study: 2680285
Drug: Fenticonazole ovule
Normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole ovule (600 mg)
Study: 2680285
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal tablet (500 mg)
Study: 1106277
Drug: Azathioprine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (3 to 4 mg/kg of body weight) plus prednisone (60 mg per day initially)
Study: 1106277
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg per day initially)
Study: 24445089
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of backward walking exercise and alpha-lipoic acid (ALA) treatment (ALA for 2 weeks, backward walking exercise for 12 weeks)
Study: 24445089
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) treatment (control group)
Study: 24445089
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of backward walking exercise and alpha-lipoic acid (ALA) treatment
Study: 16304254
Drug: Nasal or
Normalized name: Panasal Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal or inhaled beclomethasone dipropionate (BDP) administered separately or in combination for 16 weeks after a 2-week placebo run-in period
Study: 10981083
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment to a diastolic blood pressure of less than or equal to 80 mm Hg
Study: 10981083
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment to a blood pressure goal of less than 150/85 mm Hg
Study: 10981083
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment to the lowest diastolic blood pressure goal of less than or equal to 80 mm Hg
Study: 8551116
Drug: Rice paper
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice paper patch
Study: 1983509
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - Embolex‐LM, n = 464
Study: 1983509
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (Liquemin), n = 452
Study: 1983509
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - Sandoparin, n = 298
Study: 1983509
Drug: Standard heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin, n = 296
Study: 25773496
Drug: GSK256073 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 (all doses)
Study: 19169102
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (simple shoulder sling)
Study: 17222813
Drug: Enalapril (E(+):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (E(+): 10 mg/day)
Study: 17222813
Drug: Losartan (L(+):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (L(+): 50 mg/day)
Study: 17222813
Drug: Enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril + Losartan (E(+)L(+): 10 mg/day + 50 mg/day)
Study: 17222813
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (E(-)L(-))
Study: 15563440
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day iron supplementation
Study: 9241004
Drug: Bupropion 100
Normalized name: buPROPion 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 100 mg three times daily
Study: 8347437
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg od)
Study: 8347437
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg od)
Study: 3521559
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 micrograms/kg, single oral dose)
Study: 3521559
Drug: Diethylcarbamazine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (administered for eight days)
Study: 30047223
Drug: Closed-loop (CL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop (CL) insulin pump delivery